Abstract
Given the prevalence of sickle cell disease among black Americans, vexing questions of race and stigma have shadowed the history of its medical treatment. Recent developments in treating pain crises and gene therapy are part of a complex history of slow progress tinged with constant peril.

This publication has 1 reference indexed in Scilit: